Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2013

View Archived Issues

New point-of-care diagnostic biosensors for the detection of pathogens

A new allelic variant linked to the IRF3 gene

Eventus Diagnostics gains CE mark for Octava Pink breast cancer test

Sanofi details active first quarter 2013

Wellspring Biosciences presents novel mutant-specific KRas inhibitors

Newcastle disease virus developed for the treatment of prostate cancer

Results updated from phase II expansion study of SGI-110

Astellas and Drais form new partnership to develop treatment candidate for nocturia

Transgenomic and Amgen collaborate on test kits for metastatic colorectal cancer

Bayer discontinues TRUST phase II/III trial amid safety concerns

Seattle Genetics and Spirogen disclose novel anticancer agents

ChemRar and Sanofi enter scouting agreement for venture investment in Russia and Asia

Ablynx begins preclinical development of ALX-0962 for severe allergic asthma

Aileron Therapeutics completes first trial of a stapled peptide

Organizations gain grant to research TB, HIV and malaria vaccines

Yale University discloses new HIV reverse transcriptase inhibitors

FDA grants fast track status to Cubist Pharmaceuticals' QIDP candidate

AbbVie prepares novel anticancer agents

Opsona Therapeutics begins phase II study of OPN-305

The Scripps Research Institute forms agreement with Janssen Pharmaceuticals

AstraZeneca divulges novel BACE1 inhibitors

Shire reports progress for the first quarter of 2013

Brazilian researchers prepare new agents for cancer

Novel EGFR inhibitors for cancer presented by Teligene

Agile Therapeutics presents phase III results for Twirla, a novel contraceptive patch

Multiple ascending dose study of candidate for Marburg virus infection begins

GAP study of immunoglobulin in Alzheimer's disease misses primary endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...